Omega-3 fatty acid/rosuvastatin

Drug Profile

Omega-3 fatty acid/rosuvastatin

Alternative Names: HCP-1007; Omega-3/rosuvastatin; Rosuvastatin/omega-3; Rosuvastatin/omega-3 fatty acid

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihyperlipidaemics; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea (PO, Capsule)
  • 01 Mar 2013 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT01929070)
  • 01 Feb 2013 Hanmi Pharmaceutical initiates enrolment in a phase I trial for Healthy volunteers in South Korea (NCT01929070)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top